Education
About Us
Working with TipRanks
Follow Us
Biocryst Pharmaceuticals (BCRX)
NASDAQ:BCRX
Earnings Data
Report Date
Feb 25, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.03Last Year’s EPS
-0.13Same Quarter Last Year
Strong Buy
Based on 11 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call reflected a strong performance by BioCryst with significant revenue growth, successful financial maneuvers, and promising pipeline developments. However, there were some challenges, including enrollment delays and increased costs. Overall, the company's positive results and strategic decisions indicate a promising outlook.Company Guidance
Strong ORLADEYO Revenue Growth
ORLADEYO revenue increased by 37% year-over-year to $159.1 million, with $141.6 million coming from the U.S. market.
Financial Position Enhancement
Closed the sale of the European business, paid off Pharmakon debt, and entered a financing partnership with Blackstone, providing up to $400 million in cash.
Pipeline Expansion and Progress
Announced the proposed acquisition of Astria Therapeutics, adding navenibart to the pipeline, and shared positive preliminary data on BCX17725 for Netherton syndrome.
Raised ORLADEYO Revenue Guidance
Increased revenue guidance to between $590 million and $600 million for the year, even after selling the European operations.
Positive Financial Performance
Non-GAAP operating profit increased by 107% year-over-year, with a non-GAAP net income of $35.6 million and a strong cash balance of $269 million.
BCRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BCRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 03, 2025 | $7.32 | $6.86 | -6.28% |
Aug 04, 2025 | $7.95 | $8.73 | +9.81% |
May 05, 2025 | $8.93 | $11.03 | +23.52% |
Feb 24, 2025 | $9.21 | $8.29 | -9.99% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Biocryst Pharmaceuticals (BCRX) report earnings?
Biocryst Pharmaceuticals (BCRX) is schdueled to report earning on Feb 25, 2026, TBA (Confirmed).
What is Biocryst Pharmaceuticals (BCRX) earnings time?
Biocryst Pharmaceuticals (BCRX) earnings time is at Feb 25, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BCRX EPS forecast?
BCRX EPS forecast for the fiscal quarter 2025 (Q4) is 0.03.
